Skip to content
Catalyst

PapersPMID:30532573

Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure.

Diabetes, metabolic syndrome and obesity2018The record ↗

findings
7
compound
1
endpoints
7
no difference found
2
PMID:30532573
  1. Finding, moderate evidencelowersTotal cholesterol (TC)
  2. Finding, moderate evidencelowersTriglycerides
  3. Finding, moderate evidencelowersDiastolic blood pressure
  4. Finding, moderate evidencelowersLDL cholesterol
  5. Finding, moderate evidencelowersFasting blood glucose
  6. Finding, moderate evidenceno difference foundBody mass index
  7. Finding, moderate evidenceno difference foundGlycated haemoglobin (HbA1c)
Study, every finding
meta-analysis
Dose studied, every finding
1 to 19 g/d across trials, 2 to 24 weeks
  • “For the change of lipid profiles, as shown in Figure 2, the pooled result showed that spirulina supplements significantly lower the TC (12 treatment arms; WMD = −36.60 mg/dL; 95% CI: −51.87 to −21.33; P=0.0001; I =93%), LDL-C (11 treatment arms; WMD = −33.16 mg/dL; 95% CI: −50.52 to −15.75; P=0.0002; I =96%), TG (12 treatment arms; WMD = −39.20 mg/dL; 95% CI: −52.71 to −25.69; P=0.0001; I =73%), and vLDL-C (five treatment arms; WMD = −8.02 mg/dL; 95% CI: −8.77 to −7.26; P=0.0001; I =0%).”
    • Effect
      −36.6 mean difference, 95% CI −51.87 to −21.33
      Population
      Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; 12 treatment arms contributed to this estimate
    • Decreases triglycerides

      moderatereplicated ×4

      Effect
      −39.2 mean difference, 95% CI −52.71 to −25.69
      Population
      Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; 12 treatment arms contributed to this estimate
    • Effect
      −33.16 mean difference, 95% CI −50.52 to −15.75
      Population
      Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; 11 treatment arms contributed to this estimate
  • “For the change of BP, consumption with spirulina showed a significant decrease in DBP (four treatment arms; WMD = −7.17 mmHg; 95% CI: −8.57 to −5.78; P=0.0001; I =0%) but not SBP (four treatment arms; WMD = −3.49 mmHg; 95% CI: −7.19 to 0.21; P=0.06; I =50%).”
    Effect
    −7.17 mean difference, 95% CI −8.57 to −5.78
    Population
    Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; four treatment arms contributed to this estimate
  • “Finally, spirulina consumption significantly lowered FBG (eight treatment arms; WMD = −5.01 mg/dL; 95% CI: −9.78 to −0.24; P=0.04; I =77%).”
    Effect
    −5.01 mean difference, 95% CI −9.78 to −0.24
    Population
    Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; eight treatment arms contributed to this estimate

What did not

  • “No significant changes were found for body weight (seven treatment arms; WMD = −1.51 kg; 95% CI: −3.39 to 0.36; P=0.11; I =0%), BMI (five treatment arms; WMD = −0.44 (kg/m2); 95% CI: −1.87 to 0.99; P=0.54; I =71%), and HbA1c (three treatment arms; WMD = −0.34; 95% CI: −0.79 to 0.11; P=0.14; I =78%) following spirulina supplementation.”
    • Effect
      −0.44 mean difference, 95% CI −1.87 to 0.99
      Population
      Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; five treatment arms contributed to this estimate
    • Effect
      −0.34 mean difference, 95% CI −0.79 to 0.11
      Population
      Adults and children in 12 parallel-group trials (14 arms, 807 participants overall) with type 2 diabetes, HIV infection, hypertension, ischaemic heart disease or hyperlipidaemic nephrotic syndrome; three treatment arms contributed to this estimate

Study record

Design
meta-analysis
Species
human
Population
Adults and children in 12 trials (14 arms): type 2 diabetes, HIV-infected, hypertension, ischemic heart disease, hyperlipidemic nephrotic syndrome
Participants
807
Comparator
no treatment / placebo
Duration
not reported
Endpoints measured
23